Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors

Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors

ABSTRACTPD-1 checkpoint inhibitors have revolutionized the treatment of patients with different cancer histologies including melanoma, renal cell carcinoma, and non-small cell lung carcinoma. However, only a subset of patients show a dramatic clinical response to treatment. Despite intense biomarker...

Full description

Bibliographic Details
Main Authors: Sho Yoshimoto, Nicholas Chester, Ailian Xiong, Enrico Radaelli, Hong Wang, Marc Brillantes, Gayathri Gulendran, Patrick Glassman, Don L. Siegel, Nicola J. Mason
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:mAbs
Subjects:
Canine
checkpoint inhibitor
monoclonal antibody
PD-1
pharmacokinetics
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2023.2287250

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2023.2287250

Similar Items